Search results

Disruptions and shortages of drugs have become severe problems in recent years, which has triggered strong media and public interest in the topic. However, little is known about the factors that can be associated with the increased frequency of shortages. In this paper, the authors analyze the drivers of drug shortages using empirical data for Germany, the fourth largest pharmaceutical market.

The authors use a dataset provided by the German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte [BfArM]) with 425 reported shortages for drug substances (DSs) in the 24-month period between May 2017 and April 2019 and enrich the data with information from additional sources. Using logistic and negative binomial regression models, the authors analyze the impact of (1) market characteristics, (2) drug substance characteristics and (3) regulatory characteristics on the likelihood of a shortage.

The authors find that factors like market concentration, patent situation, manufacturing processes or dosage form are significantly associated with the odds of a shortage. The authors discuss the implications of these findings to reduce the frequency and severity of shortages.

The authors contribute to the empirical research on drug shortages by analyzing the impact of market characteristics, DS characteristics and regulatory characteristics on the reported shortages. The authors’ analysis provides a starting point for better prioritizing efforts to strengthen drug supply as it is currently intensely discussed healthcare authorities.

Antibiotics shortages have become an increasingly common problem in Europe because of several reasons, including the offshoring of the production of active pharmaceutical ingredients for many of these products to low production cost countries, such as China and India. The problem has deteriorated because of the Covid-19 crisis that has put most global value chains (GVCs) under great stress. This situation has boosted extensive discussions among academics, practitioners and policymakers on possible changes to the configuration of GVCs. This paper aims to focus specifically on antibiotics supply chains from the perspective of a small country (Sweden), and analyse the pros and cons of backshoring and nearshoring alternatives, as a means to reduce drug shortages.

This work adopts a systemic perspective to capture the implications of reshoring for the different stakeholders involved in the antibiotics field. The present meso-analysis, focusing at the industry level, is based on multiple sources of primary data collected between 2014 and 2021, including participation in policy-related projects and interviews with over 100 representatives of key stakeholders in the antibiotics field.

This paper shows how reshoring can address the problems of drug shortages and reduce availability risk in antibiotics’ GVCs. However, the authors show that no simple and best solution exists because both alternatives of reshoring, i.e. backshoring and nearshoring, entail pros and cons for different stakeholders. The authors conclude with implications for policymakers and managers.

The analysis of pros and cons of both backshoring and nearshoring for various stakeholders offers relevant implications for research on operations and supply management, international business and economics/political science.

This paper looks at reshoring as a policy-driven decision and provides an innovative systemic perspective to analyse the implications for different stakeholders of two reshoring options concerning the antibiotics supply chain.

This “impact pathways” paper argues that operations and supply chain management (OSCM) could help address the worsening drug shortage problem in high-income countries. This significant societal problem poses difficult challenges to stakeholders given the complex and dynamic nature of drug supply chains. OSCM scholars are well positioned to provide answers, introducing new research directions for OSCM in the process.

To substantiate this, the authors carried out a review of stakeholder reports from six European countries and the academic literature.

There is little academic research and no fundamental agreement among stakeholders about causes of shortages. Stakeholders have suggested many government measures, but little evidence exists on their comparative cost-effectiveness.

The authors discuss three pathways of impactful research on drug shortages to which OSCM could contribute: (1) Developing an evidence-based system view of drug shortages; (2) Studying the comparative cost-effectiveness of key government interventions; (3) Bringing supply chain risk management into the government and economics perspectives and vice versa. Our study provides a baseline for future COVID-19-related research on this topic.

Uganda is one of many African countries struggling to develop adequate healthcare, particularly in regard to local treatment and access to drugs. The purpose of this paper is to contribute to the understanding of how reducing supply‐chain complexity can improve health in developing countries.

This study and evaluation included 50 interviews and 27 site visits of the public healthcare system in Karamoja, northeast Uganda. A mapping of drug‐supply chains was undertaken to identify causes of stock shortages and possible solutions. A model for logistics process redesign was used for the analysis. Results were quantified with use of a simple tool developed for this specific purpose.

The main conclusion is that less supply‐chain complexity can produce higher customer service in terms of less stock shortages, while keeping costs down. By reducing lead times and uncertainty, increasing order frequencies, and moving order points and safety stocks, there may be better integration between information and goods flows and bottlenecks in the supply chain may be reduced.

While the empirical study is extensive, there are uncertainties in the data that must be taken into account. The effects of the suggested solutions remain to be analyzed and documented upon implementation.

The study was rooted in a practical problem and provides practical solutions for developing countries and agencies providing aid.

Stock shortages of life‐saving drugs are a general problem in countries with lack of financial and technical infrastructure. Improvements will impact the lives of many people.

The paper provides an understanding of the applicability of traditional logistics principles in a new context. It provides the academic community with a much‐needed in‐depth understanding of humanitarian logistics. The approach can be used in other studies.

Drawing on information processing view (IPV) theory, the objective of this study is to explore big data analytics (BDA) in pharmaceutical supply chain (PSC) for better business intelligence. Supply chain operations reference (SCOR) model is used to identify and discuss the likely benefits of BDA adoption in five processes: plan, source, make, deliver and return.

Semi-structured interviews with managers in a triad comprising pharmaceutical manufacturers, wholesalers/distributors and public hospital pharmacies were undertaken. NVivo software was used for thematic data analysis.

The findings revealed that BDA capability would be more practical and helpful in planning, delivery and return processes within PSC. Sourcing and making processes are perceived to be less beneficial.

The study informs managers about the strategic role of BDA capabilities in SCOR processes for improved business intelligence.

Adoption of BDA in SCOR processes within PSC is a step towards resolving the challenges of drug shortages, counterfeiting and inventory optimisation through timely decision. Despite its innumerable benefits of BDA, Australian PSC is far behind in BDA investment. The study advances the IPV theory by illustrating and strengthening the fact that data sharing and analytics can generate real-time business intelligence helping in better health care support through BDA-enabled PSC.

Medicine shortages have a detrimental impact on stakeholders in the pharmaceutical supply chain (PSC). Existing studies suggest that building resilience strategies can mitigate the effects of these shortages. As such, this research aims to examine whether resilience strategies can reduce the impact of medicine shortages in the United Kingdom's (UK) PSC.

A sequential mixed-methods approach that involved qualitative and quantitative research enquiry was employed in this study. The data were collected using semi-structured interviews with 23 key UK PSC actors at the qualitative stage. During the quantitative phase, 106 respondents completed the survey questionnaires. The data were analysed using partial least square-structural equation modelling (PLS-SEM).

The results revealed that reactive and proactive elements of resilience strategies helped tackle medicine shortages. Reactive strategies increased relational issues such as behavioural uncertainty, whilst proactive strategies mitigated them.

The findings suggest that PSC managers and decision-makers can benefit from adopting structural flexibility and proactive strategies, which are cost-effective measures to tackle medicine shortages. Also engaging in strategic alliances as a proactive strategy mitigates relational issues that may arise in a complex supply chain (SC).

This study is the first to provide empirical evidence of the impact of resilience strategies in mitigating medicine shortages in the UK's PSC.

The COVID-19 pandemic has affected many industries, and reports indicate that this includes the illicit drug market. Recent research suggests that the homeless are particularly vulnerable during the pandemic, and the UK Government has acted to house rough sleepers. Research is scarce regarding homeless people’s experiences of the illicit drug market. This study aims to explore homeless people’s experiences of the drug supply in the UK during COVID-19.

Eight homeless people who use illicit drugs, residing in hostels for homeless people in Southampton, participated in semi-structured one-on-one telephone-based interviews.

A thematic analysis revealed five themes: availability of drugs, presence of dealers, quality of drugs, finances and personal experiences. Participants reported varying experiences of the drug supply, with lockdown measures expressed as the main reason for reduced supplies, as users found it difficult to find dealers and generate income for purchasing drugs.

The results may lack generalisability to the wider population, such as rough sleepers and drug dealers, suggesting a need for further research into people’s experiences of the drug supply during COVID-19. Research on this topic could be more in-depth through the use of research methods that are convenient for the homeless population.

Services should invest in harm reduction services and encourage homeless people who use drugs to engage in substitution treatment. Homeless services should provide psychological support for homeless people who use drugs.

The changes in homeless people’s behaviour following the pandemic may have implications for their interactions with the rest of society (e.g. begging in town centres may reduce). These changes in behaviour may also change the way society can best support homeless people.

The results are partially consistent with other research findings about the illicit drug supply; however, they also suggest that some individuals experienced minimal change in the illicit drug supply.

In the wake of the 1988 United Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances, attention has come to be focused on money laundering. Several developed, and some developing, countries now have in place legislative and other control measures designed to enable information to be collected and to facilitate investigations with regard to investments and transfer of funds above a certain monetary limit; to confiscate assets purchased with the proceeds from the sale of controlled drugs; and, to impose stringent jail and other sentences on persons contravening the applicable drug or banking laws.

Purpose – In this chapter, we expand the definition of disaster through combining the tenets of disaster studies with the literature on risks and consequences of war and conflict-related displacement and dislocation, with a focus on the challenges that drug misuse and changing drug markets present in these contexts. We conclude with policy recommendations for successful community rebuilding with relation to drugs and drug markets following various forms of disaster, gleaned from the combination of these areas of inquiry.

Design/methodology/approach – We discuss the concepts of risk, social vulnerability, and consequences as related to traditional conceptualizations of disaster, and highlight how they can also be applied to the study of veterans returning from war. We focus the on the similarities related to drugs and drug markets.

Findings – Overall, the similar vulnerabilities, potential for trauma, and drug-related consequences experienced by both disaster survivors and veterans suggest that the experience of war and return from such an event could be considered a disaster and analyzed as such.

Originality/value of power – Few scholars have examined how to expand the definition of a disaster and what is examined in the field of disaster studies. This chapter does this by examining how war could be analyzed as a disaster. It demonstrates the parallels between war and traditional disaster.

The pandemic induced lockdown lead to supply and manufacturing disruptions that were swiftly dealt with by the Indian Pharma Industry through successful industry-government collaboration. By May 2020 production was back to normal and exports were higher than the same period in May 2019. The case deals with the processes that enabled this to happen, the policy responses and the changes that happened in the period from March 2020 to August 2020.